Kornimate/medical-research-clean huggingface dataset:
prediction of stroke-associated pneumonia

Conditions: Ischemic Stroke

Summary: stroke-associated pneumonia (sap) constitutes a clinically relevant complication of stroke, because it increases the mortality and has a negative impact on the neurological prognosis of the patient. an early identification of patients at risk for sap allowing an early initiation of antiinfective therapy may improve the prognosis. to date, no reliable prediction models or clinical scores for stroke-associated pneumonia exist. recently, it was shown that parameters indicating an impaired immune function are associated with the subsequent occurrence of sap and could therefore be used as predictors for sap. this study will develop and prospectively validate a prognostic score to predict sap based on clinical parameters. furthermore, the study examines the prognostic properties of selected immune and infectious parameters for the prediction and diagnosis of sap. the study will further address the question whether these infectious and immune parameters predict the 3-month-outcome. in a subgroup of patients, mri parameters on stroke size and localization will be assessed to investigate whether these parameters might allow prediction of sap or the 3-month-outcome.


Eligibility criteria:
inclusion criteria: * ischemic stroke in the anterior (aca, mca) and posterior cerebral circulation (pca, ba) of any severity * stroke onset within the last 36h * age ≥ 18 * consent by the patient or the legal representative exclusion criteria: * intracranial hemorrhage * signs of infection at admission (clinical / paraclinical) * pre-existing dysphagia * mechanical ventilation at admission * participation in an interventional trial

Keywords: ischemic stroke stroke-associated pneumonia prediction immune and infection parameters
personalized health education against the health damage of novel coronavirus (covid-19) outbreak in hungary

Conditions: SARS-CoV-2; Coronavirus; COVID-19; 2019-nCoV; 2019nCoV

Summary: the additional effect of personalized health education compared to general education following the internationally accepted principles will be evaluated in the prevention of the serious course of the novel coronavirus infection. it is hypothesised that personalized health education provides a greater degree of lifestyle change, thus the risk of a serious course of infection decreases.

proactive-19 is a pragmatic, randomized controlled clinical trial with adaptive "sample size re-estimation" design. volunteers will be randomized into two groups: (a) generalized health education; (b) personalized health education. participants will go through phone questioning and recommendation in 5 fields: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits, (5) alcohol consumption. both groups a and b will receive the same line of questioning to assess habits concerning these topics. in group a: questioning will be done in sequence followed by a shared minimal intervention aimed towards improvement of these factors but without any personalized recommendation. in group b: each assessment will be followed by specific and personalized recommendations. assessment will be done weekly during the first month, every second week in the second month, then monthly. considering one interim analysis for efficacy the estimated sample size is 3788 (rounded up to 3800) subject per study arm. the planned duration of the follow up is a minimum of one year.

Eligibility criteria:
the inclusion criteria are: 1. age over 60 years; 2. informed consent to participate. the exclusion criteria are: 1. confirmed covid-19 infection (active or recovered); 2. hospitalization at screening for eligibility; 3. someone was already enrolled in the study from the same community/household (to avoid potential crosstalk between the study arms).

Keywords: coronavirus health education personalized health education randomized controlled trial intensive care multi organ failure prevention
evaluation of long-term prucalopride treatment with chronic constipation in subjects aged ≥ 18 years

Conditions: Constipation

Summary: the purpose of this trial is to evaluate the long-term (24 weeks) efficacy of prucalopride versus placebo in subjects aged 18 years and older with chronic constipation.

in this phase iv trial a total of 340 subjects (170 subjects per treatment group), with chronic constipation, are planned to be randomly assigned to double-blind treatment. the trial duration for a subject can be 26 to 28 weeks in total, including a 2- to 4-week run-in phase followed by a 24-week double-blind treatment phase. the patient will complete an e-diary. adult subjects (≥18 to \<65 years of age) will take 2 mg prucalopride or matching placebo throughout the entire 24-week treatment period. elderly subjects (≥65 years of age) will start at a dose of 1 mg prucalopride or matching placebo. in case of insufficient response the daily dose has to be increased to 2 mg (i.e. changed to 2 mg prucalopride or matching placebo).

Eligibility criteria:
inclusion criteria: 1. subject is a male or non-pregnant, non-breastfeeding female out-patient ≥18 years of age (no upper age limit). 2. subject has a history of constipation. the subject reports an average of ≤2 sbm/week that result in a feeling of complete evacuation (scbm). 3. subject agrees to stop his/her current laxative treatment and is willing to use rescue medication according to the rescue rule \[bisacodyl/enemas\]. exclusion criteria: 1. subjects in whom constipation is thought to be drug-induced 2. subjects using any disallowed medication. 3. subjects who previously used prucalopride. 4. subjects suffering from secondary causes of chronic constipation.

Keywords: long term constipation digestive signs and symptoms
physical activity intervention to reduce functional health disparities among breast cancer survivors

Conditions: Breast Cancer; Physical Activity

Summary: the purpose of this research study is to determine whether a physical activity (exercise) program in the community will improve the functional and overall health status of older women with a history of breast cancer. the physical activity or exercise program is designed for all older breast cancer survivors, and in particular for african-americans and women of lower socio-economic status, who are the least likely to engage in physical activity.

specific aim #1: to determine the effect of a refined and culturally-sensitive physical activity intervention on functional outcomes at 20 and 52 weeks among older breast cancer survivors who are within five years of treatment completion for stage i-iii breast cancer (bca). specific aim #2: to examine whether race and socioeconomic status (ses) moderate the intervention effect on physical activity (pa) levels and functional outcomes at 20 and 52 weeks. specific aim #3: to examine the effect of the pa intervention on longitudinal changes in beliefs, attitudes and preferences (kaps) and pa levels, and the extent to which changes in these factors mediate intervention effect on functional outcomes. specific aim #4: to determine the effect of the pa intervention on surrogate biomarkers associated with breast cancer prognosis and functional disability.

Eligibility criteria:
inclusion criteria: * pathologically confirmed breast cancer * stage i-iii * patients who have completed treatment but are within five years of treatment completion (primary surgery, chemotherapy or radiation therapy), whichever was received last. hormonal therapy and targeted therapy are allowed * race: african-americans and non-hispanic whites exclusion criteria: * stage iv breast cancer * patients with end-stage disease, severe dementia and/or life expectancy of less than one year * inability to understand english as study instruments have not been validated in other languages * inability to provide informed consent * high-risk patients (as defined by the american college of sports medicine risk-stratification schema using the american college of sports medicine (acsm)/american heart association exercise pre-participation questionnaire) who do not receive clearance from cardiology * other medical or psychological conditions that would make participation unsafe or inhibit our ability to test our primary hypothesis, e.g. parkinson's disease, severe dementia.

Keywords: physical activity breast cancer minority african american
evaluate the safety and effectiveness of various frequency stimulation for patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: patients with an implantable electrical nerve stimulation system patient criteria included: over 18 years of age,mmse≥ 24 score; h-y stage in medicine off condition\>2.0;an ability to walk at least 10 meters independently;subscore≥2 for updrs part ii item 15;subscore \>1 for updrs part ii item 14; permissions given by informed consent. patients with serious diseases such as tumor, sever liver or kidney dysfunction were not selected in the clinical trials. subjects participating in other clinical trials related or not related to these trials were not chosen.


Eligibility criteria:
inclusion criteria: * age \>18 years of age,male or female patients * idiopathic parkinson's disease * had deep brain stimulaton implant * h-y\>2.0 in the absence of l-dopa * updrsii-14 item ≥1 * updrsii-15 item ≥2 * an ability to walk at least 10 meters independently exclusion criteria: * patients with serious diseases such as tumor, sever liver or kidney dysfunction were not selected in the clinical trials * epilepsy * pregnant female * history of severe neuropsychiatric disease * patients are taking part in other clinical trials in recent several months
acute right ventricular infarction registry

Conditions: Inferior Wall; Transmural Myocardial Infarction; Right Ventricular Dysfunction

Summary: this study aims to provide an assessment of clinical presentation, management, hospital course, and prognosis of acute right ventricular infarction presenting with or without inferior or infero-posterior wall myocardial infarction and the assessment of composite adverse clinical outcome after reperfusion in-hospital and post-discharge (in 30 days prognosis).

after fulfilling the eligibility criteria, informed consent will be obtained from all the patients regarding using data for research while maintaining anonymity.data will be collected for various patient, system, and procedure related characteristics with the help of a predefined structured proforma consisted of demographic data, clinical presentation, history and co-morbid conditions, and angiographic and procedural characteristics. all the recruited patients will be kept under observiton during the hospital stay and a telephonic follow-up will be carried out after 30-days of discharge and occurrence of the mace will be recorded. univariate and multivariable binary logistic regression analysis will be performed to determine the clinical predictors of rvi. odds ratio (or) along with 95% confidence interval (ci) will be reported. the statistical significance criteria will be set as p-value\<0.05. for data verification, 10% of the data will be cross-checked with the source document (patient file).

Eligibility criteria:
inclusion criteria: * patients of inferior, infero-lateral and infero-posterior wall mi with and without rv infarction undergoing ppci. * both male and female patients. * patients of age ≥ 18 years. exclusion criteria: • patients who will not give consent for participation.
what is the predictive value of the reflux impact scale

Conditions: Gastroesophageal Reflux Disease; GERD; Heartburn; Acid Regurgitation; Retrosternal Pain

Summary: gastric distress is a common phenomenon in our society. heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults. the yearly prevalence of recurrent stomach complaints are frequent reason for consulting a primary care physician and are an important reason for using otc medication. a good diagnosis is important as functional gerd with possible complications such as strictures and barrett's esophagus or ulcer disease with life threatening complications such as bleeding \& perforations. the clinical diagnosis of reflux disease is mainly based on symptom evaluation. this, however, is hindered by the variety of complaints with different etiology. treatment with a proton pump inhibitor can be used to confirm the diagnosis reflux disease. a major part of the patients with acid related stomach complaints indeed will experience symptom relief after starting ppi therapy. in this view, it is important to identify these patients who will react on treatment with ppi in quick, accurate, non-invasive and cheap manner. the reflux impact scale (ris) is validated, short, self explanatory questionnaire which asks for the presence \& impact of reflux symptoms. the ris is developed for pcp to aid in the evaluation \& selection of these patient who will profit from treatment with ppi. the aim of this present study is to determine which questions of the ris can be predictive for reaching treatment success with ppi. treatment success is determined by asking for patients' satisfaction \& completion of the mcmaster overall treatment evaluation heartburn questionnaire.


Eligibility criteria:
inclusion criteria: * age 18 years or older * patients with symptoms of reflux disease and or regurgitation and/or retrosternal pain probably caused by acid during the previous 7 days and for which treatment with a ppi is started. exclusion criteria: * use of ppi and/or h2-receptor antagonist in the month prior to participation in this study. * presence of alarm symptoms

Keywords: reflux impact scale (ris) predictive value treatment success patient satisfaction proton pump inhibitor gastro-esophageal reflux disease ppu
the effect of coronal restoration type on satisfaction patients.

Conditions: Quality of Life

Summary: this study aimed to evaluate the impacts of coronal restorations of endodontic treated posterior teeth (etpt) on the satisfaction and quality of patient's life. the patients who were chosen for this purpose were asked to fill in 3 questionnaires.electronic charts and files of patients who received endodontic treatment in our faculty between 2018 and 2020 were reviewed and chosen. the patients included in the study had been treated by the same endodontist and restorative dental specialist. the coronal restoration of the etpt had to be either direct composite restoration (dcr) or indirect ceramic restoration (icr). when the data of patient files and database systems were combined, 76 patients were deemed fit for this study. the patients were contacted by phone to request participation in the study. a rendezvous was created for the patients who agreed to get involved in the study, and those who came to the appointment filled in the questionnaires. demographics, the semantic differential scale, and the ohip-14 scores provided data that were entered into minitab 18 software.

this cross-sectional clinical study was approved by the ethics committee of the istanbul okan university and conducted both at its endodontics and restorative departments of dentistry faculty. a query of the nucleus database (a patient management software) was performed to identify dental charts of patients who received endodontic treatment between december 2018 and january 2020. we searched only for primary endodontic treatment of vital tooth codes, and then selected the same endodontic specialists' patients. a total of 400 teeth were identified for screening. next, a specified restorative dentistry specialist's patient searched within these patients, and 150 patients were obtained. the study was completed with 68 participants (n=34 each). then data and radiographs of patients were checked out for the eligibility criteria.

Eligibility criteria:
inclusion criteria: * (1) patients who received only one nonsurgical, single visit primary root canal therapy to one posterior tooth (premolar/molar) which has no periapical lesion and class i/ii coronal restoration, (2) patient's restoration had occlusal function for a minimum of 1 year, (3) patients who were ≥18 years old and no pregnancy or breastfeeding status (4) patients who had good oral hygiene and full dentition (5) patients who were on the american society of anesthesiology i and ii. exclusion criteria: * patients with physical disabilities and communication difficulties, periapical abscess, sinus tract, dental caries were excluded from the study. patients who had other dental treatments such prosthetic crowns, implants, dental bleaching, filling were not included in the study. those with open apex teeth were also excluded from the study.

Keywords: ohip-14 quality of life endodontically treated teeth composite resin
adaptive strategies for resilient intrinsic self-regulation in extremes (rise)

Conditions: Chronic Pain

Summary: the purpose of this study is to assess the efficacy of a resilience intervention in veterans with chronic pain compared to wait list control.

after being consented and screened for eligibility, participants completed baseline assessments and then were randomized to either the study intervention or wait list control. participants who were randomized to the study intervention completed post testing assessment measures within two weeks of the final treatment. participants who were randomized to waitlist conditions completed post testing assessment measures within 2 weeks of the end of the waitlist condition and then subsequently received the study intervention.

Eligibility criteria:
inclusion criteria: 1.18-80 years of age 2. united states veterans from the conflicts of oef/oif to vietnam era 3. self-identified chronic pain or chart diagnosis of chronic pain exclusion criteria: 1. active suicidality of suicidal intent requiring a greater than outpatient level of care (columbia suicidality rating scale screen, c-ssrs) 2. active alcohol abuse (alcohol use disorder identification test, audit-c) 3. active psychosis (psychosis screener) 4. current severe disabling illness 5. inability to participate in a small group interactive setting 6. inability to meet attendance requirement 7. neurocognitive conditions other than tbi (e.g. dementia, parkinsons, stroke) 8. concurrently receiving exposure therapy, cognitive behavior therapy, acceptance and commitment therapy
gait retraining for runners with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: tibiofemoral osteoarthritis (tfoa) is highly prevalent in older adults, and often causes symptoms and functional limitations. physical activity is widely advocated in people with tfoa, and running is an easy and accessible activity that provides many benefits on general health. however, running induces high knee loads, which could potentially contribute to symptoms of runners with tfoa. previous studies have suggested that running gait modifications can help in decreasing symptoms and knee loading in runners with knee conditions. yet, no study has been conducted in runners with tfoa. this intervention study will investigate the effects of a 4-week running gait retraining program on symptoms and running biomechanics in runners with tfoa. we hypothesize that running modifications will decrease symptoms, improve function and reduce knee loading.


Eligibility criteria:
inclusion criteria: * tfoa of grade 2 (mild) or 3 (moderate) on the kellgren and lawrence scale * report knee pain greater than or equal to 3/10 on a numerical pain rating scale (0-10) during most days of the previous month * run at least 10 km per week for a minimum of 6 months * declare being comfortable running on a treadmill for at least 30 minutes exclusion criteria: * history of traumatic knee injury * neurological or inflammatory arthritic condition * cardiovascular or cardiopulmonary disease preventing from safely performing moderate intensity running * presence of any lower limb condition affecting running (other than tfoa) * use of any oral or injected corticosteroids or viscosupplementation in the previous six months * regular use of non-steroidal anti-inflammatory drugs, analgesics or knee unloading bracing devices before, during or after running * non-english speaking
use of quantitative ultrasound to guide adaptive chemotherapy among women with breast cancer

Conditions: Breast Cancer

Summary: the primary objective of this study is to assess the feasibility of randomizing breast cancer patients to quantitative ultrasound to guide adaptive neoadjuvant chemotherapy as compared to standard clinical monitoring and therapy. the investigators have previously demonstrated that high-frequency ultrasound and spectroscopy, and recently conventional-frequency ultrasound and spectroscopy may be used to detect cell death in vitro, in situ and in vivo. the method can detect different forms of cell death and has been demonstrated to be sensitive to apoptotic, necrotic and mitotic cell death. by detecting cell death early in a treatment on the order of hours to days, rather than traditional anatomical assessments that take place weeks to months after the completion of therapy, ineffective therapies could be switched to more efficacious treatments or aggressive salvage therapy which has shown to already benefit patients. the overarching goal of this research is to transform the delivery of neoadjuvant chemotherapy using quantitative ultrasound (qus), which is non-invasive, inexpensive and portable.

this study phase ii will demonstrate the use of quantitative ultrasound to guide adaptive chemotherapy for patients with breast cancer. the primary endpoint will be measurement of improved response rate locally. this trial will enroll 240 randomized breast cancer patients to be assess with quantitative ultrasound to guide adaptive neoadjuvant chemotherapy as compared to standard clinical monitoring and therapy. we will evaluate the safety of its use and expect equivalence in this small patient population. this will allow for more accurate estimation of a needed sample size for a phase iii superiority trial.

Eligibility criteria:
inclusion criteria: 1. women ≥ 18 years of age 2. diagnosis of breast cancer with a primary tumour \>2cm in size 3. with conditions meeting criteria for chemotherapy administration 4. normal hematological blood counts (hemoglobin ≥ 100 g/l, platelet count ≥ 100 x 109, absolute neutrophil count ≥ 2.0 x109 cells per l) 5. creatinine ≤175 µmol/l 6. liver enzymes (ast and alt) ≤ 1.5 times upper limit of normal 7. cardiac function (left ventricular ejection fraction) ≥55% 8. eligible for neoadjuvant chemotherapy. exclusion criteria: 1. inflammatory breast cancer 2. contraindications to neoadjuvant treatment including pregnancy or lactation 3. past medical history of connective tissue disease 4. past history of dermatologic disease involving the breast 5. eastern cooperative group status (ecog) ≥3 6. no peripheral neuropathy of a severity of grade ≥2 7. evidence of distant metastatic disease 8. known sensitivity to components present in ultrasound gel.

Keywords: ultrasound, chemotherapy
the effect of methylphenidate on primary enuresis in children with attention deficit hyperactivity disorder

Conditions: Attention Deficit Hyperactivity Disorder; Enuresis

Summary: to assess wether methylphenidate reduces the prevalence of primary nocturnal enuresis in children with attention deficit disorder

children aged 5 - 10 years newly diagnosed with attention deficit hyperactivity disorder who report primary nocturnal enuresis, investigators will obtain baseline data (from parents/caregivers) on their sleep habits and enuresis characteristics by questionnaire. after 6 weeks of methylphenidate therapy, prescribed for the attention deficit, a new questionnaire will be filled.

Eligibility criteria:
inclusion criteria: * new diagnosis of attention deficit hyperactivity disorder * history of primary nocturnal enuresis * normal neurological examination exclusion criteria: * anatomical abnormality of the genitourinary system * concommitant treatment, pharmacological/behavioral for enuresis * concommitant diurnal enuresis